Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA uses complex statistical analyses to determine the likelihood that a fetus is carrying a disorder such as Down’s syndrome or other prenatal genetic abnormalities. The opportunity to grow IONA in Asian markets is well recognised and the strategic acquisition of Yourgene Bioscience will accelerate this. Meanwhile, Premaitha has moved quickly to expand the availability of IONA throughout Europe and the Middle East, thereby offsetting the impact of financial difficulties being encountered by its largest customer in fiscal 2017.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Expanding global distribution network
- Published:
17 Mar 2017 -
Author:
Martin Hall -
Pages:
12
Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA uses complex statistical analyses to determine the likelihood that a fetus is carrying a disorder such as Down’s syndrome or other prenatal genetic abnormalities. The opportunity to grow IONA in Asian markets is well recognised and the strategic acquisition of Yourgene Bioscience will accelerate this. Meanwhile, Premaitha has moved quickly to expand the availability of IONA throughout Europe and the Middle East, thereby offsetting the impact of financial difficulties being encountered by its largest customer in fiscal 2017.